2seventy bio’s Abecma Wins FDA Approval for Multiple Myeloma

An update from 2seventy bio (TSVT) is now available.

2seventy bio, Inc. and Bristol Myers Squibb have announced the FDA approval of Abecma, a new treatment for adult patients with relapsed or refractory multiple myeloma who have previously undergone at least two other therapies. This groundbreaking decision, based on the successful outcome of the Phase 3 KarMMa-3 trial, marks a significant advancement for patients battling this challenging form of cancer.

For detailed information about TSVT stock, go to TipRanks’ Stock Analysis page.